Concomitant antiplatelet or anticoagulant use 
Calculated creatinine clearance < 30 mL/min by Cockcroft-Gault formula 
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times upper limit of normal (ULN) 
Total bilirubin > 2 x ULN 
Thrombocytopenia < 50 x 10 gigalitres (Gl) 
High bleeding risk or spontaneously prolonged prothrombin time or activated partial thromboplastin time > 1.5 x ULN 
Body weight <50 or >120 kg 
Concomitant use of CYP3A4 or p-glycoprotein inducers or inhibitors 
Use of Ginkgo biloba or St. John's Wort within 14 days before first dose of study drug 
Dexamethasone use within last 3 months 
Women of Childbearing potential without proper contraceptive measures, pregnancy or breast feeding 
Life expectancy less than 3 months 
Inability to swallow or issues with malabsorption 
Any other medical, social, logistical, geographical or psychological factors, which in the opinion of the investigator, would prohibit follow-up, compliance and study completion       
    

NCT02749617_exc_T1
Drug
antiplatelet
NCT02749617_exc_T2
Drug
anticoagulant
NCT02749617_exc_T3
Temporal
Concomitant
NCT02749617_exc_T4
Measurement
Calculated creatinine clearance
NCT02749617_exc_T5
Value
< 30 mL/min
NCT02749617_exc_T6
Measurement
Cockcroft-Gault formula
NCT02749617_exc_T7
Measurement
Alanine aminotransferase (ALT)
NCT02749617_exc_T8
Measurement
aspartate aminotransferase (AST)
NCT02749617_exc_T9
Value
> 3 times upper limit of normal (ULN)
NCT02749617_exc_T10
Measurement
Total bilirubin
NCT02749617_exc_T11
Value
> 2 x ULN
NCT02749617_exc_T12
Measurement
Thrombocytopenia
NCT02749617_exc_T13
Value
< 50 x 10 gigalitres (Gl)
NCT02749617_exc_T14
Condition
High bleeding risk
NCT02749617_exc_T15
Condition
prolonged prothrombin time
NCT02749617_exc_T16
Qualifier
spontaneously
NCT02749617_exc_T17
Measurement
activated partial thromboplastin time
NCT02749617_exc_T18
Value
> 1.5 x ULN
NCT02749617_exc_T19
Condition
Body weight
NCT02749617_exc_T20
Value
<50 kg
NCT02749617_exc_T21
Value
>120 kg
NCT02749617_exc_T22
Scope
<50 or >120 kg
NCT02749617_exc_T23
Drug
CYP3A4
NCT02749617_exc_T24
Drug
p-glycoprotein inducers
NCT02749617_exc_T25
Drug
p-glycoprotein inhibitors
NCT02749617_exc_T26
Temporal
Concomitant
NCT02749617_exc_T27
Drug
Ginkgo biloba
NCT02749617_exc_T30
Drug
Dexamethasone
NCT02749617_exc_T31
Temporal
within last 3 months
NCT02749617_exc_T32
Person
Women
NCT02749617_exc_T33
Condition
Childbearing potential
NCT02749617_exc_T34
Procedure
contraceptive measures
NCT02749617_exc_T35
Negation
without
NCT02749617_exc_T36
Condition
pregnancy
NCT02749617_exc_T37
Observation
breast feeding
NCT02749617_exc_T38
Observation
Life expectancy
NCT02749617_exc_T39
Value
less than 3 months
NCT02749617_exc_T40
Condition
Inability to swallow
NCT02749617_exc_T41
Condition
issues with malabsorption
NCT02749617_exc_T28
Drug
St. John's Wort
NCT02749617_exc_T29
Temporal
within 14 days before first dose of study drug
NCT02749617_exc_T44
Reference_point
first dose of study drug
NCT02749617_exc_T46
Multiplier
first dose
NCT02749617_exc_T47
Drug
study drug
NCT02749617_exc_T48
Scope
Ginkgo biloba or St. John's Wort